Learning objectives

After watching this webinar, participants will:

• understand initiation strategies using individualised DAPT to treat ACS patients with HBR who are undergoing PCI;
• be able to assess recurrent bleeding and thrombotic risk in patients;
• comprehend available RC trials and RWE studies with P2Y12 inhibitors; and
• understand current options of antiplatelet treatment to mitigate bleeding risk in ACS patients.

Needs assessment and expected educational outcome

To understand the clinical implications of the ACR-HBR study, including initiation strategies using dual antiplatelet therapy individualised for ACS patients undergoing PCI. 

Main topic

• Acute coronary syndrome

Related topics

• Acute Coronary Syndromes - Treatment - Pharmacotherapy - Antiplatelet Agents
• High bleeding risk (HBR)
• Coronary artery disease

Session information

This webinar is designed for Cardiologists in training as well as senior doctors taking care for CAD patients with ACS across the spectrum of low to high bleeding risk patients.

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.

Technical settings

The webinar is available on PC and tablets. The use of a smartphone is not recommended.

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).